Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Diagnostic-driven management of invasive fungal disease in hematology in the era of prophylaxis and resistance emergence: Dutch courage?

de Kort EA, Maertens J, Verweij PE, Rijnders BJA, Blijlevens NMA.

Med Mycol. 2019 Jun 1;57(Supplement_3):S267-S273. doi: 10.1093/mmy/myz026.

PMID:
31292660
2.

Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study.

Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, Blijlevens NMA, Vonk AG, Rijnders B, Verweij PE, Lagrou K, Maertens J.

Med Mycol. 2019 Jul 9. pii: myz079. doi: 10.1093/mmy/myz079. [Epub ahead of print]

PMID:
31290552
3.

Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines.

Bowen JM, Gibson RJ, Coller JK, Blijlevens N, Bossi P, Al-Dasooqi N, Bateman EH, Chiang K, de Mooij C, Mayo B, Stringer AM, Tissing W, Wardill HR, van Sebille YZA, Ranna V, Vaddi A, Keefe DM, Lalla RV, Cheng KKF, Elad S; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2019 Jul 8. doi: 10.1007/s00520-019-04892-0. [Epub ahead of print]

PMID:
31286233
4.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Sanz G, Stauder R, Holm MS, Mittelman M, Mądry K, Malcovati L, Tatic A, Almeida AM, Germing U, Savic A, Gredelj Šimec N, Culligan D, Itzykson R, Guerci-Bresler A, Slama B, van de Loosdrecht A, van Marrewijk C, Droste J, Blijlevens N, van Kraaij M, Bowen D, de Witte T, Smith A; EUMDS Registry Participants.

Haematologica. 2019 Jul 5. pii: haematol.2018.212332. doi: 10.3324/haematol.2018.212332. [Epub ahead of print]

5.

Impact of red blood cell transfusion dose density on progression-free survival in lower-risk myelodysplastic syndromes patients.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Čermák J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Šimec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants.

Haematologica. 2019 Jun 6. pii: haematol.2018.212217. doi: 10.3324/haematol.2018.212217. [Epub ahead of print]

6.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis JH, Marchand T, Reményi P, Cahn JY, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J.

Ann Hematol. 2019 Jul;98(7):1755-1763. doi: 10.1007/s00277-019-03669-z. Epub 2019 Apr 16.

PMID:
30993417
7.

Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects.

de Kort EA, van Dorp S, Blijlevens NMA, van der Velden WJFM.

Bone Marrow Transplant. 2019 Apr 10. doi: 10.1038/s41409-019-0526-0. [Epub ahead of print] No abstract available.

PMID:
30971779
8.

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.

de Kort EA, de Lil HS, Bremmers MEJ, van Groningen LFJ, Blijlevens NMA, Huls G, Brüggemann RJM, van Dorp S, van der Velden WJFM.

PLoS One. 2019 Mar 21;14(3):e0213913. doi: 10.1371/journal.pone.0213913. eCollection 2019.

9.

Editorial: Knowledge of gastrointestinal toxicity mechanisms is paving the way for improved assessment and management of patient supportive care.

Stringer AM, Blijlevens N.

Curr Opin Support Palliat Care. 2019 Jun;13(2):111-113. doi: 10.1097/SPC.0000000000000424. No abstract available.

PMID:
30883402
10.

Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Janssen L, Frambach SJCM, Allard NAE, Hopman MTE, Schirris TJJ, Voermans NC, Rodenburg RJ, Blijlevens NMA, Timmers S.

Leukemia. 2019 Aug;33(8):2116-2120. doi: 10.1038/s41375-019-0443-7. Epub 2019 Mar 14. No abstract available.

PMID:
30872782
11.

Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.

Poort H, Onghena P, Abrahams HJG, Jim HSL, Jacobsen PB, Blijlevens NMA, Knoop H.

J Clin Psychol Med Settings. 2019 Feb 12. doi: 10.1007/s10880-019-09607-5. [Epub ahead of print]

PMID:
30747340
12.

Salivary Changes before and after Hematopoietic Stem Cell Transplantation: A Systematic Review.

van Leeuwen SJM, Potting CMJ, Huysmans MDNJM, Blijlevens NMA.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1055-1061. doi: 10.1016/j.bbmt.2019.01.026. Epub 2019 Jan 30. Review.

13.

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, Franquet T, Blijlevens NMA, Maertens JA; European Conference on Infections in Leukemia (ECIL).

Leukemia. 2019 Apr;33(4):844-862. doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30. Review.

14.

The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.

Ector GICG, Govers TM, Westerweel PE, Grutters JPC, Blijlevens NMA.

Leuk Lymphoma. 2019 Jun;60(6):1485-1492. doi: 10.1080/10428194.2018.1535113. Epub 2019 Jan 22.

PMID:
30668187
15.

Cognitive Behavior Therapy for Persistent Severe Fatigue in Childhood Cancer Survivors: A Pilot Study.

Boonstra A, Gielissen M, van Dulmen-den Broeder E, Blijlevens N, Knoop H, Loonen J.

J Pediatr Hematol Oncol. 2019 May;41(4):313-318. doi: 10.1097/MPH.0000000000001345.

PMID:
30475298
16.

Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis.

Saes JL, Simons A, de Munnik SA, Nijziel MR, Blijlevens NMA, Jongmans MC, van der Reijden BA, Smit Y, Brons PP, van Heerde WL, Schols SEM.

Haemophilia. 2019 Jan;25(1):127-135. doi: 10.1111/hae.13638. Epub 2018 Nov 15.

PMID:
30431218
17.

Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, Masereeuw R, Netea MG, Levine JE, Morales G, Ferrara JL, Blijlevens NMA, van Oosterhout YVJM, Stelljes M, van der Velden WJFM.

Biol Blood Marrow Transplant. 2019 Apr;25(4):712-719. doi: 10.1016/j.bbmt.2018.10.020. Epub 2018 Nov 3.

PMID:
30399420
18.

Long-Term Outcome of Patients With a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care.

de Vries VA, Müller MCA, Arbous MS, Biemond BJ, Blijlevens NMA, Kusadasi N, Span LRF, Vlaar APJ, van Westerloo DJ, Kluin-Nelemans HC, van den Bergh WM; HEMA-ICU Study Group.

Crit Care Med. 2019 Feb;47(2):e120-e128. doi: 10.1097/CCM.0000000000003526.

19.

Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia.

Fiets RB, Staal AHJ, Cramer GE, Blijlevens NMA.

Neth J Med. 2018 Sep;76(7):330-335.

20.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis.

Muilwijk EW, Maertens JA, van der Velden WJFM, Ter Heine R, Colbers A, Burger DM, Andes D, Theunissen K, Blijlevens NMA, Brüggemann RJM.

J Antimicrob Chemother. 2018 Nov 1;73(11):3095-3101. doi: 10.1093/jac/dky324.

PMID:
30137340
21.

Predictors of short-term and long-term mortality in critically ill patients admitted to the intensive care unit following allogeneic stem cell transplantation.

van der Heiden PLJ, Arbous MS, van Beers EJ, van den Bergh WM, le Cessie S, Demandt AMP, Eefting M, Hess C, Kusadasi N, Marijt WAF, van Mook WNKA, Müller MCA, Tuinman PR, van Vliet M, van Westerloo DJ, Blijlevens NMA; HEMA-ICU Study Group.

Bone Marrow Transplant. 2019 Mar;54(3):418-424. doi: 10.1038/s41409-018-0277-3. Epub 2018 Aug 6.

PMID:
30082850
22.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
23.

Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.

Vreugdenhil B, van der Velden WJFM, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, Blijlevens NMA, Brüggemann RJM.

Br J Clin Pharmacol. 2018 Sep;84(9):1980-1988. doi: 10.1111/bcp.13627. Epub 2018 Jun 19.

24.

Impact of Oral Side Effects from Conditioning Therapy Before Hematopoietic Stem Cell Transplantation: Protocol for a Multicenter Study.

Brennan MT, Hasséus B, Hovan AJ, Raber-Durlacher JE, Blijlevens NM, Huysmans MC, Garming Legert K, Johansson JE, Moore CG, von Bültzingslöwen I.

JMIR Res Protoc. 2018 Apr 23;7(4):e103. doi: 10.2196/resprot.8982.

25.

Early salivary changes in multiple myeloma patients undergoing autologous HSCT.

van Leeuwen S, Proctor GB, Potting C, Ten Hoopen S, van Groningen L, Bronkhorst EM, Blijlevens N, Huysmans M.

Oral Dis. 2018 Sep;24(6):972-982. doi: 10.1111/odi.12866. Epub 2018 May 4.

PMID:
29637662
26.

Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model.

Loonen JJ, Blijlevens NM, Prins J, Dona DJ, Den Hartogh J, Senden T, van Dulmen-Den Broeder E, van der Velden K, Hermens RP.

Int J Integr Care. 2018 Jan 16;18(1):4. doi: 10.5334/ijic.3046.

27.

Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation.

Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, Martin A, Snowden JA, Mohty M, Maertens J, Passweg J, Petersen E, Nihtinen A, Isaksson C, Milpied N, Rohlich PS, Deconinck E, Crawley C, Ledoux MP, Hoek J, Nagler A, Styczynski J.

Clin Infect Dis. 2018 Aug 1;67(4):564-572. doi: 10.1093/cid/ciy150.

PMID:
29481599
28.

Time trend analysis of long term outcome of patients with haematological malignancies admitted at dutch intensive care units.

de Vries VA, Müller MCA, Sesmu Arbous M, Biemond BJ, Blijlevens NMA, Kusadasi N, Choi GCW, Vlaar APJ, van Westerloo DJ, Kluin-Nelemans HC, van den Bergh WM; HEMA-ICU Study Group.

Br J Haematol. 2018 Apr;181(1):68-76. doi: 10.1111/bjh.15140. Epub 2018 Feb 22.

PMID:
29468848
29.

Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.

de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, Cermak J, Sanz G, Stauder R, Mittelman M, Hellström-Lindberg E, Malcovati L, Langemeijer S, Skov-Holm M, Mądry K, Germing U, Almeida AM, Tatic A, Savic A, Šimec NG, van Marrewijk C, Guerci-Bresler A, Sanhes L, Luño E, Culligan D, Beyne-Rauzy O, Burgstaller S, Blijlevens N, Bowen D, de Witte T.

Leuk Res. 2018 Apr;67:21-26. doi: 10.1016/j.leukres.2018.01.022. Epub 2018 Jan 31.

30.

Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study.

Lestrade PP, van der Velden WJFM, Bouwman F, Stoop FJ, Blijlevens NMA, Melchers WJG, Verweij PE, Donnelly JP.

J Antimicrob Chemother. 2018 May 1;73(5):1389-1394. doi: 10.1093/jac/dkx527.

PMID:
29394399
31.

Physical exercise prior to hematopoietic stem cell transplantation: A feasibility study.

van Haren IEPM, Staal JB, Potting CM, Atsma F, Hoogeboom TJ, Blijlevens NMA, Nijhuis-van der Sanden MWG.

Physiother Theory Pract. 2018 Oct;34(10):747-756. doi: 10.1080/09593985.2018.1423655. Epub 2018 Jan 16.

PMID:
29336645
32.

Red blood cell transfusion support and management of secondary iron overload in patients with haematological malignancies in the Netherlands: a survey.

Hoeks MPA, Middelburg RA, Romeijn B, Blijlevens NMA, van Kraaij MGJ, Zwaginga JJ.

Vox Sang. 2018 Feb;113(2):152-159. doi: 10.1111/vox.12617. Epub 2017 Dec 19.

PMID:
29266372
33.

[Current dilemmas on the transmission of hepatitis E virus].

de Weerd-de Jong E, Peters AM, Rahamat-Langendoen JC, Blijlevens NMA.

Ned Tijdschr Geneeskd. 2017;161:D1951. Review. Dutch.

PMID:
29192575
34.

Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.

Cany J, Roeven MWH, Hoogstad-van Evert JS, Hobo W, Maas F, Franco Fernandez R, Blijlevens NMA, van der Velden WJ, Huls G, Jansen JH, Schaap NPM, Dolstra H.

Blood. 2018 Jan 11;131(2):202-214. doi: 10.1182/blood-2017-06-790204. Epub 2017 Nov 14.

35.

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee.

Haematologica. 2018 Jan;103(1):69-79. doi: 10.3324/haematol.2017.171884. Epub 2017 Nov 9.

36.

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation.

van der Velden WJFM, de Weerd-de Jong EC, de Haan AFJ, Blijlevens NMA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):410-412. doi: 10.1016/j.bbmt.2017.10.020. Epub 2017 Oct 16. No abstract available.

37.

Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients.

Timmermans K, Leijte GP, Kox M, Scheffer GJ, Blijlevens NMA, Pickkers PP.

Acta Haematol. 2017;138(1):39-43. doi: 10.1159/000477530. Epub 2017 Jul 20.

PMID:
28723682
38.

Biomarkers and non-invasive tests for gastrointestinal mucositis.

Kuiken NSS, Rings EHHM, Blijlevens NMA, Tissing WJE.

Support Care Cancer. 2017 Sep;25(9):2933-2941. doi: 10.1007/s00520-017-3752-2. Epub 2017 May 24. Review.

39.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance.

de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenková D, Vallespí T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellström-Lindberg E, Čermák J, Stauder R, Tatic A, Holm MS, Malcovati L, Mądry K, Droste J, Blijlevens N, de Witte T, Germing U.

Ann Hematol. 2017 Jul;96(7):1105-1112. doi: 10.1007/s00277-017-3009-7. Epub 2017 May 20.

40.

Targeting the interleukin-1 pathway in patients with hematological disorders.

de Mooij CEM, Netea MG, van der Velden WJFM, Blijlevens NMA.

Blood. 2017 Jun 15;129(24):3155-3164. doi: 10.1182/blood-2016-12-754994. Epub 2017 May 8. Review.

41.

Clonal evolution in myelodysplastic syndromes.

da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, Stevens-Kroef MJ, Cermak J, Shiraishi Y, Chiba K, Tanaka H, Miyano S, de Witte T, Blijlevens NMA, Muus P, Huls G, van der Reijden BA, Ogawa S, Jansen JH.

Nat Commun. 2017 Apr 21;8:15099. doi: 10.1038/ncomms15099.

42.

Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients.

Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Snijders TJF, Cornelissen J, Bos G, Pruijt HFM, de Graaf AO, van der Reijden BA, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM.

Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.

43.

TFR2-related haemochromatosis in the Netherlands: a cause of arthralgia in young adulthood.

Peters TM, Meulders AF, Redert K, Cuijpers ML, Rennings AJ, Janssen MC, Blijlevens NM, Swinkels DW.

Neth J Med. 2017 Mar;75(2):56-64.

44.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.

Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T.

Ann Hematol. 2016 Dec;95(12):1971-1978. Epub 2016 Sep 20.

45.

Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.

Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6.

46.

The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.

Roeven MW, Thordardottir S, Kohela A, Maas F, Preijers F, Jansen JH, Blijlevens NM, Cany J, Schaap N, Dolstra H.

Stem Cells Dev. 2015 Dec 15;24(24):2886-98. doi: 10.1089/scd.2014.0597. Epub 2015 Oct 28.

PMID:
26414401
47.

Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.

van Groningen LF, Liefferink AM, de Haan AF, Schaap NP, Donnelly JP, Blijlevens NM, van der Velden WJ.

Biol Blood Marrow Transplant. 2016 Jan;22(1):179-82. doi: 10.1016/j.bbmt.2015.08.039. Epub 2015 Sep 18.

48.

Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics.

Stienen JJ, Hermens RP, Wennekes L, van de Schans SA, van der Maazen RW, Dekker HM, Liefers J, van Krieken JH, Blijlevens NM, Ottevanger PB; PEARL study group.

BMC Cancer. 2015 Aug 8;15:578. doi: 10.1186/s12885-015-1547-8.

49.

[Severe inflammation during recovery from neutropenia: the immune reconstitution inflammatory syndrome following chemotherapy].

van Lier DP, Janssen NA, Snoeren MM, Verweij PE, Blijlevens NM, van der Velden WJ.

Ned Tijdschr Geneeskd. 2015;159:A8968. Review. Dutch.

PMID:
26246060
50.

Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice.

Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Brüggemann RJ.

Curr Opin Pharmacol. 2015 Oct;24:38-44. doi: 10.1016/j.coph.2015.07.002. Epub 2015 Jul 25. Review.

PMID:
26218924

Supplemental Content

Loading ...
Support Center